Chinese Pharma Companies Pushing for Global Reach with focus on R&D

In targeted therapies, drugs are used to “target” cancerous cells without having an adverse impact on normal cells during cancer treatments. In...

Coherus to move beyond biosimilars with a cancer immunotherapy drug

Coherus Biosciences, known for developing biosimilars, had decided to extend its objectives in February.  The company has now stepped into developing innovative...

Amgen to buy Teneobio for $2.5B to further its antibody interests

Amgen isn’t leaning on its laurels even after getting a prompt approval for its carefully manufactured KRAS lung cancer drug, Lumakras, as...

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

Bristol-Myers Squibb and Agenus enter a $1.56bn definitive agreement to support cancer programme

An exclusive international license contract of $1.56 billion has been signed between BMS (Bristol Myers Squibb) and Agenus, for AGEN1777

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...
- Advertisement -

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm